Last reviewed · How we verify
Group 3: 0.2% Chlorhexidine
Group 3: 0.2% Chlorhexidine is a Small molecule drug developed by Dr Meru S. It is currently in Phase 1 development. Also known as: Rexidine®.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Group 3: 0.2% Chlorhexidine |
|---|---|
| Also known as | Rexidine® |
| Sponsor | Dr Meru S |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Immediate Restoration of a New Implant With High Primary Stability (NA)
- Effectiveness of Herbal vs Chlorhexidine Mouthwashes in Improving Oral Health in Schoolchildren (NA)
- Clinical and Microbiological Comparison of 0.12% CHX and 0.05% CHX+0.05%CPC Mouthwashes in TPS Patients (NA)
- EFFECT OF PERIODONTAL TREATMENT ON ALZHEIMER DISEASE-ASSOCIATED OUTCOMES (NA)
- Preoperative Auricular Acupuncture in Elective Cesarean Section. (NA)
- Effectiveness of Biodentine v/s Calcium Hydroxide as Indirect Pulp Capping Materials (NA)
- Horizontal Ridge Augmentation Using Polyvinylidene Fluoride Versus Titanium Mesh Membranes (NA)
- Comparative Effects of Two Oral Antiseptics Used as an Adjuvant in the Treatment of Periodontitis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Group 3: 0.2% Chlorhexidine CI brief — competitive landscape report
- Group 3: 0.2% Chlorhexidine updates RSS · CI watch RSS
- Dr Meru S portfolio CI
Frequently asked questions about Group 3: 0.2% Chlorhexidine
What is Group 3: 0.2% Chlorhexidine?
Who makes Group 3: 0.2% Chlorhexidine?
Is Group 3: 0.2% Chlorhexidine also known as anything else?
What development phase is Group 3: 0.2% Chlorhexidine in?
Related
- Manufacturer: Dr Meru S — full pipeline
- Also known as: Rexidine®
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing